Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000411312 | SCV000486924 | likely pathogenic | Glycogen storage disease, type V | 2016-09-08 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000411312 | SCV002293549 | pathogenic | Glycogen storage disease, type V | 2023-04-15 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 371363). Disruption of this splice site has been observed in individuals with glycogen storage disease type V (GSD V), also known as McArdle disease (PMID: 8279469, 22250184, 30415384). This variant is present in population databases (rs747513238, gnomAD 0.02%). This sequence change affects a donor splice site in intron 14 of the PYGM gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PYGM are known to be pathogenic (PMID: 8316268, 16786513). |
Fulgent Genetics, |
RCV000411312 | SCV002812667 | likely pathogenic | Glycogen storage disease, type V | 2022-03-04 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000411312 | SCV004207265 | likely pathogenic | Glycogen storage disease, type V | 2023-06-11 | criteria provided, single submitter | clinical testing |